Oncology‑derived peripheral blood mononuclear cells (PBMCs) are isolated from patients diagnosed with solid tumors and hematologic malignancies, providing a clinically relevant immune cell source for immuno‑oncology research. These PBMCs capture tumor‑driven systemic immune alterations and are ideal for studying tumor–immune interactions, immune cell activation and exhaustion, checkpoint pathways, and treatment response in cancer.

Available with donor‑specific clinical and demographic data (tumor type, stage, therapy status), oncology‑derived PBMCs support translational applications including immunotherapy development, biomarker discovery, patient stratification studies, and humanized in vivo models. They are well-suited for flow cytometry, functional assays, transcriptomics, and proteomics to profile anti‑tumor immune responses across diverse cancer indications.